Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia

January 31, 2007 updated by: Hospital Mutua de Terrassa

Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia

The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine production in patients with pneumococcal pneumonia.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Bacterial alveolar invasion is followed by a compartmentalized inflammatory response. Data suggest that some antimicrobials may induce a differential release of cytokines, with the potential of either accelerating or down regulating cytokine production.

The aim of our study was to compare the effects of ceftriaxone compared with levofloxacin on cytokine systemic concentrations in patients with pneumococcal pneumonia.

Study Type

Interventional

Enrollment

45

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Terrassa, Barcelona, Spain, 08221
        • Hospital Mútua de Terrassa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients with an acute febrile respiratory illness accompanied by a new radiographic infiltrate consistent with this diagnosis.
  • and with a confirmed pneumococcal aetiology

Exclusion Criteria:

  • age < 18 years,
  • pneumonia distal to endobronchial obstruction,
  • pulmonary tuberculosis,
  • bronchiectasis,
  • known allergy to B-lactams or fluoroquinolones,
  • underlying systemic autoimmune disease
  • immunocompromised states including patients on maintenance oral corticosteroids, HIV infection,
  • pregnancy,
  • patients that received antimicrobial therapy in the 15 days preceding the current episode and those who had received fluoroquinolones in the last month, or non steroidal anti-inflammatory therapy in the last two weeks.
  • Patients with renal failure (serum creatinine > 2 mg / dL),
  • and patients with a documented pneumococcal pneumonia in the previous 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Circulating levels of pro and anti-inflammatory cytokines at 0h, 24, 72 h and 120 h from inclusion

Secondary Outcome Measures

Outcome Measure
the relationship between cytokine expression, clinical variables and severity of disease.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: ESTHER CALBO, MD, Hospital Mútua de Terrassa
  • Principal Investigator: MONTSERRAT ALSINA, MD, Hospital Mutua Terrassa
  • Principal Investigator: MARIONA XERCAVINS, MD, Hospital Mútua de Terrassa
  • Principal Investigator: EVA CUCHI, MD, Hospital Mútua de Terrassa
  • Principal Investigator: MONICA RODRIGUEZ-CARBALLEIRA, PhD, Hospital Mútua de Terrassa
  • Study Director: JAVIER GARAU, PhD, Hospital Mútua de Terrassa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2004

Study Completion

September 1, 2005

Study Registration Dates

First Submitted

January 31, 2007

First Submitted That Met QC Criteria

January 31, 2007

First Posted (Estimate)

February 1, 2007

Study Record Updates

Last Update Posted (Estimate)

February 1, 2007

Last Update Submitted That Met QC Criteria

January 31, 2007

Last Verified

January 1, 2007

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.